This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Accuray (ARAY) Down 6.7% Since Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are WMGI & ARAY Neck and Neck? Let's Take a Closer Look
by Zacks Equity Research
Wright Medical (WMGI) scores higher than Accuray (ARAY) when it comes to current-year earnings and growth projections.
Accuray (ARAY) Q1 Loss Wider Than Expected, Gross Orders Rise
by Zacks Equity Research
Accuray's (ARAY) flagship Radixact System drives Q1 results; strong EBITDA guidance instils hope.
Accuray (ARAY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of -16.67% and 0.77%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Accuray (ARAY) Q1 Earnings Preview: What to Look Out For
by Zacks Equity Research
Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Varian (VAR) Buys Noona to Boost Oncology Software Services
by Zacks Equity Research
Varian's (VAR) latest move provides it significant exposure to the cloud-based oncology services market.
Accuray's (ARAY) Radixact System Used First Time in Germany
by Zacks Equity Research
Accuray's (ARAY) flagship radiotherapy systems have lucrative prospects.
Accuray's CyberKnife Manages Prostate Cancer Effectively
by Zacks Equity Research
Accuray's (ARAY) flagship CyberKnife is the only robotic radiotherapy system.
3 Stocks to Watch as Bots Take Bigger Strides in US Healthcare
by Sreyoshi Mukherjee
Robotics and mechatronics shape up the U.S. medical industry; three stocks that catch the eye.
Accuray (ARAY) Earnings Beat in Q4, Gross Orders Rise Y/Y
by Zacks Equity Research
Accuray's (ARAY) flagship Radixact System drives Q4 results; overseas gains raise hope.
Accuray's Radixact Gets AERB Nod in India, Prospects Solid
by Zacks Equity Research
The Atomic Energy Regulatory Board (AERB) approves Accuray's (ARAY) Radixact X9 in India; exposes the company to AI and Mechatronic trends.
New Strong Sell Stocks for June 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Here's Why You Should Sell Accuray (ARAY) Stock Right Now
by Zacks Equity Research
Regulatory issues regarding Onrad, intense competition in the radiation oncology market and unfavorable foreign exchange rate are significant challenges for Accuray (ARAY).
New Strong Sell Stocks for June 4th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Accuray (ARAY) Down 13.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for May 23rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for May 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for May 9th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Accuray (ARAY) Q3 Loss Wider Than Estimates, Revenues Top
by Zacks Equity Research
Radixact System and major software overhaul drive Accuray (ARAY) in Q3.
Accuray Radixact Picked by India's Apollo for Cancer Treatment
by Zacks Equity Research
Accuray's (ARAY) flagship Radixact radiotherapy platform to help in cancer treatment at Apollo Hospital Group in New Delhi and Chennai, India.
Accuray's CyberKnife Treats First Patient at Erasmus MC
by Zacks Equity Research
Accuray (ARAY) and Erasmus MC partner to develop CyberKnife platform to simplify diagnosis of oligometastatic diseases.
Accuray Banks on Acquisition & Partnership Amid Competition
by Zacks Equity Research
Accuray's (ARAY) partnerships with Premier and Amerinet are expected to help the company gain significant penetration in hospitals and oncology centers.
Varian Medical Receives Regulatory Nod for Sirtex Buyout
by Zacks Equity Research
The acquisition of Sirtex will fortify Varian Medical's (VAR) footprint in Australia. The transaction is likely to close in late May 2018.
Here's Why Small-Cap HealthCare ETFs & Stocks Are Good Picks
by Sanghamitra Saha
Two reasons why small-cap healthcare stocks and ETFs could be winners in the coming days.
Accuray Gains on Radixact Unit, Solid Geographical Foothold
by Zacks Equity Research
Radixact and TomoTherapy along with solid global prospects are the key catalysts for Accuray (ARAY).